(520) 505 8792
Magnesium glycinate offers a promising and well-tolerated option for migraine management. Its high bioavailability and gentle effect on the digestive system make it a suitable choice for many individuals suffering from migraine.
The FDA has just approved fremanezumab (Ajovy) for the preventive treatment of episodic migraine in children and adolescents ages 6–17.
Alexander Feoktistov, MD, PhD, director of the Synergy Integrative Headache Clinic, addressed the unique aspects of cluster headaches as well as other TAC, or trigeminal autonomic cephalalgia at the American Academy of Pain Medicine’s 2018 annual meeting.
FDA approves Rizafilm, the first oral thin film using IntelGenx proprietary drug delivery technology, for the acute treatment of migraine with or without aura.
The prescription wearable neuromodulation device, Nerivio, was recently cleared by the FDA for preventive treatment of migraine.
FDA has approved a new nasal spray for acute treatment of migraine in adults.
A brief discussion about a balanced approach to migraine treatment that may include lifestyle modifications, medications, and the state-of-the-art approved neuromodulation devices that may help treat and prevent migraine attacks.
Dr. Alex’s interview with MassDevice medical network about novel options in migraine management: CGRP active drugs and non-invasive neuromodulation devices approved for migraine treatment.
Here Dr. Alex Feoktistov discusses migraine symptoms and diagnosis as well acute and prophylactic treatment options.